alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 95 studies by Wang X marked Peer-reviewed (page 2 of 4) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 95 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Sex differences in the association between tau PET and cognitive performance in a non-Hispanic White cohort with preclinical AD

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-08-28

Women show stronger associations between tau PET and cognitive outcomes in preclinical AD. 3 key findings →

Participants: 343 Evidence: low

Full summary, score breakdown and related studies → Original source

The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-09-03

APOE ε4 positive genotype may cause familial aggregation, and the investigation of multiple interventions targeting APOE pathological function to reduce the risk for this disease warrants attention. 1 key finding →

Participants: 119 Evidence: low

Full summary, score breakdown and related studies → Original source

Caregiver burden and prevalence of depression, anxiety and sleep disturbances in Alzheimer's disease caregivers in China

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of clinical nursing 2016-11-23

Depression, anxiety and sleep problems are the main challenges that are faced by family caregivers of patients with Alzheimer's disease. 4 key findings →

Design: cross-sectional Participants: 309 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Translational psychiatry 2017-01-31

Exposure to particulate matter (PM) in the ambient air and its interactions with APOE alleles may contribute to the acceleration of brain aging and the pathogenesis of Alzheimer's disease (AD). 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Trajectories of the Hippocampal Subfields Atrophy in the Alzheimer's Disease: A Structural Imaging Study

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Frontiers in neuroinformatics 2019-03-22

The trend changes in the hippocampus subfields and further illustrates that SCD is the preclinical stage of AD earlier than aMCI. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association between lipocalin-2 and mild cognitive impairment or dementia: A systematic review and meta-analysis of population-based evidence

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Ageing research reviews 2023-06-15

In peripheral blood, the overall pooled results showed no significant difference in LCN2 across Alzheimer's disease (AD), MCI and control groups. 3 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Immunity 2022-12-14

Obesity-induced chronic liver inflammation is a hallmark of nonalcoholic steatohepatitis (NASH)-an aggressive form of nonalcoholic fatty liver disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multimodal MRI reveals impaired glymphatic function with choroid plexus enlargement and cerebrospinal fluid expansion in alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Scientific reports 2025-08-19

There is increasing evidence that cerebrospinal fluid (CSF) circulation plays a key role in the pathophysiology of Alzheimer's disease (AD), although the underlying mechanisms remain poorly understood. 2 key findings →

Participants: 188 Evidence: low

Full summary, score breakdown and related studies → Original source

Serum neurofilament light chain and inflammatory cytokines as biomarkers for early detection of mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Scientific reports 2024-04-20

To investigate the association between serum neurofilament light chain (NfL) levels, inflammatory cytokines, and cognitive function to assess their utility in the early detection of mild cognitive impairment (MCI). 3 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's research & therapy 2019-06-03

Individuals with SCD had an altered cortical surface area, and APOE genotype and anxiety symptoms are modified factors on the cortical surface area decrease in SCD. 4 key findings →

Participants: 65 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Smartphone automated motor and speech analysis for early detection of Alzheimer's disease and Parkinson's disease: Validation of TapTalk across 20 different devices

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2024-10-23

Validation of TapTalk across a range of devices is an important step in the development of smartphone-based telemedicine and was achieved in this study. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Validation of a Computerized Cognitive Training Tool to Assess Cognitive Impairment and Enable Differentiation Between Mild Cognitive Impairment and Dementia

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of Alzheimer's disease : JAD 2023-01-01

CCT can be used to assess cognitive status and detect dementia in patients with cognitive impairment. 1 key finding →

Participants: 116 Evidence: low

Full summary, score breakdown and related studies → Original source

Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2008-12-02

Mitochondrial dysfunction is a prominent feature of Alzheimer disease but the underlying mechanism is unclear. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

TREM2 variants and risk of Alzheimer's disease: a meta-analysis

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2015-06-03

Recent studies show that heterozygous variant of triggering receptor expressed on myeloid cells 2 (TREM2) increase the risk of Alzheimer's disease (AD) but with inconclusive results. 3 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Neurovascular glial unit: A target of phytotherapy for cognitive impairments

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Phytomedicine : international journal of phytotherapy and phytopharmacology 2023-08-02

Herbal medicines demonstrate great potential to prevent cognitive impairment. 1 key finding →

Design: systematic review Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Associations of risk genes with onset age and plasma biomarkers of Alzheimer's disease: a large case-control study in mainland China

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2022-01-09

Most genetic studies concerning risk genes in Alzheimer's disease (AD) are from Caucasian populations, whereas the data remain limited in the Chinese population. 4 key findings →

Participants: 3,604 Evidence: low

Full summary, score breakdown and related studies → Original source

Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE)

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2026-03-13

Non-elevated plasma p-tau181 results impacted the diagnosis and use of amyloid PET imaging in a memory clinic. 5 key findings →

Design: cohort Participants: 100 Evidence: early

Full summary, score breakdown and related studies → Original source Free full text

HMOX1-LDHB interaction promotes ferroptosis by inducing mitochondrial dysfunction in foamy macrophages during advanced atherosclerosis

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Developmental cell 2024-12-27

Advanced atherosclerosis is the pathological basis for acute cardiovascular events, with significant residual risk of recurrent clinical events despite contemporary treatment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Insight into cerebral microvessel endothelial regulation of cognitive impairment: A systematic review of the causes and consequences

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Experimental neurology 2024-12-13

Research on cognitive impairment (CI) has increasingly focused on the central nervous system, identifying numerous neuronal targets and circuits of relevance for CI pathogenesis and treatment. 1 key finding →

Design: systematic review Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events